Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

AMLX

Amylyx Pharmaceuticals Inc

Sep 12 • 04:00PM ET

11.65

-0.19 -1.60 %

Healthcare • Biotechnology • USA • NASD

Peers: BIIB VRTX BMRN ALNY SRPT NBIX ACAD SAGE RARE CYTK

| Held by: IWM VTI VXF IWO DWAS IBB SCHA VTWO IWC AVSC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.50	Insider Own	25.39%	Shs Outstand	89.16M	Perf Week	14.22%
Market Cap	1.04B	Forward P/E	-	EPS next Y	-1.43	Insider Trans	-0.42%	Shs Float	66.53M	Perf Month	40.36%
Enterprise Value	863.96M	PEG	-	EPS next Q	-0.46	Inst Own	84.74%	Short Float	12.64%	Perf Quarter	111.05%
Income	-187.60M	P/S	-	EPS this Y	59.36%	Inst Trans	13.84%	Short Ratio	4.96	Perf Half Y	217.44%
Sales	-0.25M	P/B	6.19	EPS next Y	20.50%	ROA	-71.23%	Short Interest	8.41M	Perf YTD	208.20%
Book/sh	1.88	P/C	5.74	EPS next 5Y	29.80%	ROE	-87.42%	52W High	12.25 -4.90%	Perf Year	337.97%
Cash/sh	2.03	P/FCF	-	EPS past 3/5Y	-42.83% -78.71%	ROIC	-108.33%	52W Low	2.47 371.66%	Perf 3Y	-34.92%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	574.28% 127.75%	Gross Margin	697.19%	Volatility	5.81% 6.08%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-2.45%	Oper. Margin	64567.07%	ATR (14)	0.58	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.72	Sales Y/Y TTM	-100.08%	Profit Margin	75341.37%	RSI (14)	76.42	Recom	1.11
Dividend Gr. 3/5Y	- -	Current Ratio	8.72	EPS Q/Q	56.50%	SMA20	21.53%	Beta	-0.42	Target Price	12.62
Payout	-	Debt/Eq	0.04	Sales Q/Q	100.00%	SMA50	35.86%	Rel Volume	1.23	Prev Close	11.84
Employees	123	LT Debt/Eq	0.03	Earnings	Aug 07 BMO	SMA200	116.33%	Avg Volume	1.70M	Price	11.65
IPO	Jan 07, 2022	Option/Short	Yes / Yes	EPS/Sales Surpr.	-3.51% -	Trades		Volume	2,079,921	Change	-1.60%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-10-25	Resumed	Goldman	Buy	$10
Jun-24-25	Initiated	Guggenheim	Buy	$17
Jun-17-25	Initiated	Citigroup	Buy	$12
May-30-25	Initiated	TD Cowen	Buy
Apr-07-25	Upgrade	Mizuho	Neutral → Outperform	$7
Nov-18-24	Upgrade	Robert W. Baird	Neutral → Outperform	$3 → $11
Oct-23-24	Upgrade	BofA Securities	Neutral → Buy	$4.20 → $10
Mar-18-24	Downgrade	Mizuho	Buy → Neutral	$32 → $4
Mar-11-24	Downgrade	Robert W. Baird	Outperform → Neutral	$37 → $4
Mar-11-24	Downgrade	Leerink Partners	Outperform → Market Perform	$27 → $4
Mar-08-24	Downgrade	Goldman	Buy → Neutral
Mar-08-24	Downgrade	Evercore ISI	Outperform → In-line
Jan-03-24	Initiated	Robert W. Baird	Outperform	$37
Dec-12-23	Initiated	Deutsche Bank	Buy	$36
Jul-24-23	Upgrade	Goldman	Neutral → Buy	$45 → $49
Mar-31-23	Initiated	Mizuho	Buy	$52
Jan-05-23	Initiated	BofA Securities	Buy	$50
May-25-22	Initiated	Citigroup	Buy	$21
Apr-01-22	Downgrade	Goldman	Buy → Neutral	$36 → $10

Show Previous Ratings

Sep-10-25 12:06AM	Amylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering of Common Stock (Business Wire) +12.56%
Sep-09-25 04:01PM	Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock (Business Wire)
Aug-27-25 12:35PM	Amylyx culls rare neurological disorder programme after trial failure (Pharmaceutical Technology)
12:24PM	Amylyx Halts Rare Brain Disorder Drug Program After Disappointing Trial (Benzinga)
07:22AM	Amylyx drug comes up short; Sanofi names new CMO (BioPharma Dive)
07:00AM	Loading…
07:00AM	Amylyx Pharmaceuticals to Discontinue ORION Program of AMX0035 for Progressive Supranuclear Palsy (PSP) (Business Wire)
Aug-19-25 12:07AM	H.C. Wainwright, Leerink Partners, and TD Cowen Reaffirm 'Buy' Ratings on Amylyx Pharmaceuticals, Inc. (AMLX) (Insider Monkey)
Aug-07-25 07:00AM	Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results (Business Wire)
Jul-31-25 09:00AM	Amylyx Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025 (Business Wire)
Jul-15-25 08:58AM	Amylyx Pharmaceuticals Shares Promising Avexitide Data for Post-Bariatric Hypoglycemia at ENDO 2025, Phase 3 Enrollment Nears Completion (Insider Monkey)
Jul-14-25 11:52AM	Amylyx presents new exploratory analyses from avexitide trials for PBH (Clinical Trials Arena) +9.51%
Jul-13-25 05:00PM	Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025 (Business Wire)
Jul-08-25 07:00AM	Amylyx Pharmaceuticals to Host Event to Discuss Post-bariatric Hypoglycemia and Avexitide at ENDO 2025 (Business Wire)
Jun-27-25 07:56AM	Why Shares in Amylyx Pharmaceuticals Soared This Week (Motley Fool)
Jun-25-25 03:27AM	After myriad failures, a new wave of ALS drugs approaches (Pharma Voice)
12:46PM	Loading…
Jun-24-25 12:46PM	Amylyx Pharmaceuticals Gains FDA Fast Track for ALS Drug AMX0114 (Insider Monkey) +27.69%
Jun-03-25 07:00AM	Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis (Business Wire)
May-21-25 07:00AM	Amylyx Pharmaceuticals to Participate in Upcoming June Investor Conferences (Business Wire)
May-20-25 09:55AM	Wall Street Analysts See a 105.22% Upside in Amylyx Pharmaceuticals (AMLX): Can the Stock Really Move This High? (Zacks)
May-12-25 07:00AM	Amylyx Pharmaceuticals Announces Positive Long-Term Results from Phase 2 HELIOS Clinical Trial of AMX0035 in People with Wolfram Syndrome (Business Wire)
May-09-25 03:12AM	Amylyx Pharmaceuticals Inc (AMLX) Q1 2025 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
May-08-25 07:00AM	Amylyx Pharmaceuticals Reports First Quarter 2025 Financial Results (Business Wire) -5.95%
May-07-25 06:00PM	Here are the major earnings before the open tomorrow (Seeking Alpha)
08:00AM	Amylyx Pharmaceuticals to Participate in Upcoming May Investor Conferences (Business Wire)
May-01-25 09:00AM	Amylyx Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025 (Business Wire)
06:06AM	Amylyx doses first subject in trial of post-bariatric hypoglycaemia treatment (Clinical Trials Arena)
Apr-30-25 07:00AM	Amylyx Pharmaceuticals Announces First Participant Dosed in Pivotal Phase 3 LUCIDITY Trial of Avexitide in Post-Bariatric Hypoglycemia (Business Wire)
Apr-16-25 11:22AM	Is Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) the Best Biotech Penny Stock to Buy According to Hedge Funds? (Insider Monkey)
Apr-11-25 08:11AM	Amgen says Imdelltra extended survival; Parker Institute adds new leaders (BioPharma Dive)
Apr-10-25 07:03AM	First subject dosed in Amylyxs Phase I trial of ALS therapy (Clinical Trials Arena)
07:00AM	Loading…
Apr-09-25 07:00AM	Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 1, Multiple Ascending Dose LUMINA Trial of AMX0114 in People Living with Amyotrophic Lateral Sclerosis (Business Wire) +5.44%
Apr-02-25 09:00AM	Amylyx Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference (Business Wire) +13.17%
Mar-27-25 10:17AM	Is Amylyx Pharmaceuticals (AMLX) The Hot Biotech Stock Under $5? (InsiderMonkey)
Mar-05-25 10:01AM	Amylyx Pharmaceuticals Inc (AMLX) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com) +11.63%
Mar-04-25 06:00AM	Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
Mar-03-25 07:18AM	Amylyx Pharmaceuticals Inc (AMLX) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com) -8.54%
Feb-25-25 09:00AM	Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences (Business Wire)
Feb-24-25 09:00AM	Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025 (Business Wire) -9.09%
Feb-10-25 09:00AM	Amylyx Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (Business Wire)
Jan-31-25 12:00PM	Amylyx Pharmaceuticals (AMLX) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Jan-22-25 05:00AM	Intellia makes progress on HAE study; 2 more China drug deals (BioPharma Dive)
Jan-21-25 09:00AM	Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis (Business Wire)
Jan-10-25 08:26AM	Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock (Business Wire) -7.16%
Jan-09-25 07:30PM	Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock (Business Wire)
Jan-06-25 09:00AM	Amylyx Pharmaceuticals Appoints Dan Monahan as Chief Commercial Officer (Business Wire) -5.54%
Dec-30-24 02:52PM	Why Is Amylyx Pharmaceuticals (AMLX) Among the Best Biotech Penny Stocks to Invest in Now? (Insider Monkey)
Dec-05-24 07:35AM	Amylyx announces design of LUCIDITY clinical trial (TipRanks) -5.51%
Dec-04-24 07:30AM	Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia (Business Wire)
Nov-27-24 09:00AM	Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference (Business Wire) +5.32%
Nov-08-24 02:11AM	Amylyx Pharmaceuticals Inc (AMLX) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
01:33AM	Q3 2024 Amylyx Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-07-24 07:00AM	Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results (Business Wire) +5.14%
Nov-04-24 09:00AM	Amylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024 (Business Wire)
Oct-25-24 09:05PM	Perceptive Advisors LLC's Strategic Acquisition in Amylyx Pharmaceuticals Inc (GuruFocus.com) +8.37%
Oct-19-24 11:12AM	Amylyx Pharmaceuticals (AMLX): Leading Nano Cap in Neurodegenerative Disease Treatments (Insider Monkey)
Oct-18-24 07:34AM	Amylyxs AMX0035 shows promise in Phase II Wolfram syndrome trial (Clinical Trials Arena) +21.94%
07:26AM	Why Amylyx Pharmaceuticals Stock Was So Healthy This Week (Motley Fool)
07:04AM	PTC rebuffed again by EMA; Novartis licenses China-based biotechs cancer drug (BioPharma Dive)
Oct-17-24 09:00AM	Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome (Business Wire)
Oct-15-24 09:00AM	Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024 (Business Wire) +10.06%
Oct-09-24 05:32PM	Amylyx Pharmaceuticals Inc (AMLX) Q2 2024 Earnings Call Highlights: Strategic Pipeline ... (GuruFocus.com)
Sep-09-24 07:17PM	Director Karen Firestone Acquires 50,000 Shares of Amylyx Pharmaceuticals Inc (AMLX) (GuruFocus.com) +6.33% +5.56%
Sep-06-24 01:49AM	Director MILNE GEORGE M JR Acquires 100,000 Shares of Amylyx Pharmaceuticals Inc (AMLX) (GuruFocus.com) +7.73%
Aug-28-24 08:30AM	Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Aug-12-24 09:00AM	Amylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer's Disease Pathology and Neurodegeneration (Business Wire)
Aug-08-24 07:00AM	Amylyx Pharmaceuticals Reports Second Quarter 2024 Financial Results (Business Wire)
Aug-05-24 09:00AM	Amylyx Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024 (Business Wire)
04:32AM	EC grants orphan drug status for Amylyxs Wolfram treatment (Pharmaceutical Technology)
Aug-02-24 09:00AM	Amylyx Pharmaceuticals Receives Orphan Drug Designation From the European Commission for AMX0035 for the Treatment of Wolfram Syndrome (Business Wire)
Jul-10-24 10:53AM	Amylyx to rebuild pipeline with $35m Phase III ready GLP-1RA acquisition (Clinical Trials Arena) +25.45%
07:00AM	Amylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist (Avexitide) with FDA Breakthrough Therapy Designation (Business Wire)
03:00AM	Amylyx, with GLP-1 buy, doubles down on blood sugar drugs (BioPharma Dive)
Jul-09-24 04:01PM	Amylyx Pharmaceuticals to Host Conference Call to Discuss the Acquisition of Avexitide (Business Wire)
Jun-28-24 11:02AM	Amylyx ventures into metabolic diseases market with $35.1m deal (Pharmaceutical Technology)
Jun-04-24 09:00AM	Amylyx Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire)
May-14-24 07:25AM	Mizuho Cuts Price Target on Amylyx Pharmaceuticals to $3 From $4, Keeps Neutral Rating (MT Newswires)
May-10-24 03:54PM	Amylyx Pharmaceuticals Reports Q1 2024 Financial Results (GuruFocus.com) -7.14%
12:47PM	Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 08:15AM	Amylyx Pharmaceuticals, Inc. (AMLX) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Amylyx Pharmaceuticals Reports First Quarter 2024 Financial Results (Business Wire)
May-08-24 09:00AM	Amylyx Pharmaceuticals to Present at the 2024 Bank of America Health Care Conference (Business Wire)
May-02-24 09:00AM	Amylyx Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024 (Business Wire)
Apr-30-24 12:02PM	Trials to watch: Four ALS drugs to keep an eye on (Clinical Trials Arena)
Apr-10-24 03:14PM	Amylyx Pharmaceuticals' Investigational Drug Shows Improved Pancreatic Function In Patients With Inherited Disorder (Benzinga) -7.87%
09:00AM	Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome (Business Wire)
Apr-08-24 09:00AM	Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024 (Business Wire)
Apr-04-24 01:20PM	Amylyx (AMLX) Withdraws ALS Drug, Cuts Workforce by 70% (Zacks)
10:05AM	ALS drug will be pulled from US market after study showed patients didn't benefit (Associated Press Finance)
07:52AM	UPDATE 1-Amylyx Pharma to remove ALS drug from US, Canada markets (Reuters)
07:43AM	Amylyx Is Cutting 70% of Its Workforce and Pulling ALS Drug From the Market (Barrons.com)
07:07AM	Amylyx Pharmaceuticals to remove ALS drug from US, Canada markets (Reuters)
07:00AM	Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO/ALBRIOZA from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy (Business Wire)
06:09AM	Amylyx to pull ALS drug from market in rare move (BioPharma Dive)
Apr-03-24 05:45AM	Shareholders of Amylyx Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights - AMLX (PR Newswire)
Apr-01-24 07:30PM	Amylyx Pharmaceuticals Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information (GlobeNewswire)
Mar-27-24 07:36AM	European study finds popular ALS drug ineffective (BioPharma Dive) +5.11%
Mar-25-24 02:33PM	Investors Sue Amylyx Pharmaceuticals (AMLX) After Analyst Questions RELYVRIO Data Hagens Berman (GlobeNewswire)
Mar-14-24 06:49PM	3 Pharma Stocks to Sell in March Before They Crash & Burn (InvestorPlace) -7.85%
09:00AM	Amylyx Pharmaceuticals Appoints Bernhardt Zeiher, MD, FCCP, FACP, to its Board of Directors (Business Wire)
Mar-13-24 10:00AM	SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyx (PR Newswire)

Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). Its commercial product is Relyvrio, also known as Albrioza in Canada. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mazzariello Gina	Chief Legal Officer	Aug 13 '25	Sale	8.34	15,000	125,046	156,969	Aug 14 04:20 PM
Mazzariello Gina	Chief Legal Officer	Aug 12 '25	Sale	8.07	15,000	121,102	171,969	Aug 14 04:20 PM
GINA MAZZARIELLO	Officer	Aug 12 '25	Proposed Sale	7.82	30,000	234,600		Aug 12 04:25 PM
FRATES JAMES M	Chief Financial Officer	Mar 31 '25	Sale	3.47	10,896	37,806	290,988	Apr 02 05:22 PM
Bedrosian Camille L	Chief Medical Officer	Mar 31 '25	Sale	3.47	12,425	43,082	194,375	Apr 02 05:14 PM
Mazzariello Gina	Chief Legal Officer	Mar 31 '25	Sale	3.48	9,192	31,954	187,969	Apr 02 05:12 PM
Cohen Joshua B	Co-Chief Executive Officer	Mar 31 '25	Sale	3.47	21,490	74,482	3,355,280	Apr 02 04:57 PM
Klee Justin B.	Co-Chief Executive Officer	Mar 31 '25	Sale	3.46	21,490	74,454	3,355,276	Apr 02 04:52 PM
Zeiher Bernhardt G	Director	Mar 20 '25	Buy	3.70	10,000	37,005	10,000	Mar 24 04:15 PM
Klee Justin B.	Co-Chief Executive Officer	Mar 03 '25	Sale	3.15	4,595	14,483	3,196,648	Mar 05 04:35 PM
Cohen Joshua B	Co-Chief Executive Officer	Mar 03 '25	Sale	3.17	4,595	14,549	3,196,652	Mar 05 04:32 PM
Mazzariello Gina	Chief Legal Officer	Mar 03 '25	Sale	3.12	1,611	5,022	133,310	Mar 05 04:32 PM
Mazzariello Gina	Chief Legal Officer	Feb 24 '25	Sale	3.15	4,169	13,145	134,921	Feb 26 04:35 PM
Klee Justin B.	Co-Chief Executive Officer	Feb 05 '25	Option Exercise	1.57	36,310	57,007	3,201,243	Feb 06 08:17 PM
Mazzariello Gina	Chief Legal Officer	Feb 03 '25	Sale	3.49	3,678	12,839	139,090	Feb 05 04:58 PM
Cohen Joshua B	Co-Chief Executive Officer	Feb 03 '25	Sale	3.47	11,851	41,108	3,201,247	Feb 05 04:55 PM
Klee Justin B.	Co-Chief Executive Officer	Feb 03 '25	Sale	3.47	11,855	41,104	3,164,933	Feb 05 04:54 PM
Klee Justin B.	Co-Chief Executive Officer	Jan 06 '25	Sale	4.04	7,471	30,202	3,176,788	Jan 08 05:29 PM
Cohen Joshua B	Co-Chief Executive Officer	Jan 06 '25	Sale	4.05	7,471	30,232	3,213,098	Jan 08 05:26 PM
Bedrosian Camille L	Chief Medical Officer	Dec 02 '24	Sale	5.54	5,421	30,007	138,380	Dec 03 05:21 PM
Klee Justin B.	Co-Chief Executive Officer	Nov 04 '24	Option Exercise	1.57	63,690	99,993	3,184,259	Nov 06 07:24 PM
Klee Justin B.	Co-Chief Executive Officer	Sep 30 '24	Sale	3.20	18,589	59,429	3,120,569	Oct 02 06:53 PM
Cohen Joshua B	Co-Chief Executive Officer	Sep 30 '24	Sale	3.20	18,589	59,414	3,220,569	Oct 02 06:53 PM
Bedrosian Camille L	Chief Medical Officer	Sep 30 '24	Sale	3.20	11,442	36,559	143,801	Oct 02 06:50 PM
Mazzariello Gina	Chief Legal Officer	Sep 30 '24	Sale	3.20	8,709	27,840	142,768	Oct 02 06:48 PM
Cohen Joshua B	Co-Chief Executive Officer	Sep 23 '24	Option Exercise	1.57	1,857	2,915	3,239,158	Sep 25 05:56 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AMLX

Amylyx Pharmaceuticals Inc

Upgrade your FINVIZ experience